Wallace Capital Management Has Boosted By $575,200 Its Glaxosmithkline Plc (GSK) Holding; Cardiovascular Systems (CSII) Sellers Increased By 2.8% Their Shorts

March 15, 2018 - By Maria Brooks

Wallace Capital Management Inc increased Glaxosmithkline Plc (GSK) stake by 8.74% reported in 2017Q3 SEC filing. Wallace Capital Management Inc acquired 14,380 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Wallace Capital Management Inc holds 178,883 shares with $7.26M value, up from 164,503 last quarter. Glaxosmithkline Plc now has $90.08 billion valuation. The stock decreased 0.44% or $0.165 during the last trading session, reaching $36.945. About 1.07 million shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since March 15, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

Cardiovascular Systems Inc (NASDAQ:CSII) had an increase of 2.8% in short interest. CSII’s SI was 1.04M shares in March as released by FINRA. Its up 2.8% from 1.01M shares previously. With 265,200 avg volume, 4 days are for Cardiovascular Systems Inc (NASDAQ:CSII)’s short sellers to cover CSII’s short positions. The SI to Cardiovascular Systems Inc’s float is 3.15%. The stock decreased 1.86% or $0.46 during the last trading session, reaching $24.23. About 58,144 shares traded. Cardiovascular Systems, Inc. (NASDAQ:CSII) has risen 113.78% since March 15, 2017 and is uptrending. It has outperformed by 97.08% the S&P500.

Investors sentiment increased to 1.02 in Q3 2017. Its up 0.23, from 0.79 in 2017Q2. It improved, as 16 investors sold Cardiovascular Systems, Inc. shares while 50 reduced holdings. 10 funds opened positions while 42 raised stakes. 24.82 million shares or 3.05% more from 24.09 million shares in 2017Q2 were reported. Invesco Limited owns 231,131 shares for 0% of their portfolio. Tiaa Cref Inv Mngmt Limited Liability Co has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Balyasny Asset Mgmt Limited Liability Com has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Citadel Advsrs Limited Liability Company stated it has 125,568 shares or 0% of all its holdings. Strs Ohio invested 0% of its portfolio in Cardiovascular Systems, Inc. (NASDAQ:CSII). 29,279 were reported by Timpani Cap Management Ltd Llc. 24,755 are owned by Manufacturers Life Company The. Essex Invest Mngmt invested in 0.34% or 87,579 shares. Nuveen Asset Mngmt Llc owns 46,935 shares. Fred Alger Management stated it has 0.06% in Cardiovascular Systems, Inc. (NASDAQ:CSII). New Jersey-based State Of New Jersey Common Pension Fund D has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Jpmorgan Chase & Co reported 1,478 shares stake. Capital Fund Mngmt Sa holds 0% of its portfolio in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 17,800 shares. 111,100 were accumulated by Teton. Cortina Asset Mgmt Llc, Wisconsin-based fund reported 872,363 shares.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $804.88 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It currently has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Among 9 analysts covering Cardiovascular Systems (NASDAQ:CSII), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Cardiovascular Systems had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Bank of America given on Wednesday, June 21. On Wednesday, June 29 the stock rating was maintained by Needham with “Buy”. As per Thursday, August 3, the company rating was maintained by Needham. As per Friday, July 14, the company rating was maintained by Needham. The firm earned “Buy” rating on Thursday, October 8 by Needham. Leerink Swann downgraded the stock to “Market Perform” rating in Thursday, October 8 report. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) earned “Strong Buy” rating by Needham on Thursday, August 6. The company was downgraded on Thursday, September 3 by Zacks. Needham maintained it with “Buy” rating and $32.0 target in Thursday, January 26 report. Leerink Swann upgraded the shares of CSII in report on Monday, August 22 to “Outperform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: